Post-vaccination T cell immunity to omicron
Frontiers in immunology
; 13, 2022.
Article
in English
| EuropePMC | ID: covidwho-1998874
ABSTRACT
In late 2021, the omicron variant of SARS Coronavirus 2 (SARS-CoV-2) emerged and replaced the previously dominant delta strain. Effectiveness of COVID-19 vaccines against omicron has been challenging to estimate in clinical studies or is not available for all vaccines or populations of interest. T cell function can be predictive of vaccine longevity and effectiveness against disease, likely in a more robust way than antibody neutralization. In this mini review, we summarize the evidence on T cell immunity against omicron including effects of boosters, homologous versus heterologous regimens, hybrid immunity, memory responses and vaccine product. Overall, T cell reactivity in post-vaccine specimens is largely preserved against omicron, indicating that vaccines utilizing the parental antigen continue to be protective against disease caused by the omicron variant.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Topics:
Vaccines
/
Variants
Language:
English
Journal:
Frontiers in immunology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS